Latest Drug development biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

3PBIOVIAN and INC partner to expand access to oncology treatments in Colombia through biosimilar development

by 3PBIOVIAN

4 months ago
biosimilar monoclonal antibody (mAb), Instituto Nacional de Cancerología de Colombia (INC), 3PBIOVIAN

3PBIOVIAN and the Colombia INC has signed a contract to carry out the development of a biosimilar monoclonal antibody (mAb) for an oncology indication, marking the first biosimilar mAb to be developed...

Coacervados derivados de proteínas mamíferas: una nueva vía para optimizar la transfección

by Abyntek

4 months ago
transfección, coacervados

Estos microcompartimentos pueden encapsular ADN o ARN y fusionarse con la membrana celular de forma natural, liberando su contenido con una eficiencia sorprendentemente alta y una toxicidad mucho meno...

ELISA Tradicional vs Instant ELISA: Ventajas en el laboratorio

by Abyntek

4 months ago
ELISA Tradicional, Instant ELISA de Abylabel

Mientras que los ELISAs clásicos requieren múltiples fases de incubación, lavados y preparación manual de reactivos, los Instant ELISA de Abylabel están diseñados para ofrecer resultados en meno...

UAB compound designated orphan drug to advance towards a new treatment for spinal cord injury

by Universitat Autònoma de Barcelona (UAB)

3 months ago
Maresin-1 (MaR1), spinal cord injuries.

The European Medicines Agency (EMA) has designated as an orphan drug a compound based on the bioactive lipid molecule Maresin-1 (MaR1), currently being investigated by a research team from the UAB for...

Aptadel Therapeutics raises 2 million euros and prepares a new round to bring the project to the clinical phase stage

by Parc Científic de Barcelona

3 months ago
ApDC, Ewing’s sarcoma, Aptadel Therapeutics, ADEL‑101

Aptadel Therapeutics takes another step forward in the development of its treatment for Ewing’s sarcoma. The biotechnology company has closed a bridge round of 2 million euros with the entry o...

MTBVAC moves toward its final stage: the vaccine candidate that could mark a turning point in the fight against tuberculosis

by Asebio

3 months ago
MTBVAC, tuberculosis

MTBVAC is based directly on Mycobacterium tuberculosis, the human pathogen, whereas BCG is derived from Mycobacterium bovis. This means that MTBVAC retains key antigens present in the original pathoge...

Drug development timeline: how early characterization prevents regulatory delays

by AMSbiopharma

3 months ago
Drug development, IND, AQbD

The modern drug development timeline is highly shaped by manufacturing readiness, analytical understanding, and regulatory alignment. While innovation in therapeutic modalities has accelerated target ...

53Biologics drives its expansion in GMP biomanufacturing with an investment led by Ren Life Sciences and supported by Inveready

by 53Biologics

3 months ago
Ren Life Sciences, Inveready, 53Biologics

Biotechnology company 53Biologics, specialized in the development and manufacturing of biologic drugs, has announced the closing of a strategic funding round led by European private equity firm Ren Li...

La FDA aprueba en Estados Unidos el primer medicamento de terapia génica desarrollado a partir de una investigación española

by CIBERER - Centro de Investigación Biomédica en Red de Enfermedades Raras

3 months ago
KRESLADI, deficiencia de adhesión leucocitaria de tipo I (LAD-I), Rocket Pharma, terapia génica

La Agencia Estadounidense de Alimentos y Medicamentosha aprobado el medicamento de terapia génica denominado KRESLADI™ (marnetegragene autotemcel) de la empresa Rocket Pharma para el tratamiento de...

Why GMP Readiness Starts During Drug Development, Not at Clinical Phase

by 53Biologics

3 months ago
GMP, Drug Development

Most biotech teams assume GMP readiness begins when a product enters clinical phases. In reality, the foundations of GMP are built much earlier, during drug development, often without being explicitly...

First clinical results of next-generation BRAF inhibitor against BRAF V600-mutant solid tumors

by VHIO

3 months ago
mosperafenib, BRAFi, advanced BRAF V600-mutant solid tumors.

Sponsored by F. Hoffmann-La Roche Ltd, in collaboration with Vall d’Hebron Institute of Oncology (VHIO), a first-in-human clinical trial was designed to assess the safety, maximum tolerated dose, an...

GAT Therapeutics and the University of Barcelona outline a new therapeutic strategy for interstitial lung diseases

by Parc Científic de Barcelona

3 months ago
GAT Therapeutics, Interstitial lung diseases, GTX-11, TGFβ signalling pathway

GTX-11, developed by GAT Therapeutics and protected by patent, is a small oral molecule that modulates the TGFβ signalling pathway, a key factor in fibrotic processes, characterised by the excessive ...